Abstract
The function of the Toll-like receptor (TLR) family members has been extensively studied in the recent decades. The TLR family is generally involved in the defense against microbial infections. TLRs are expressed mainly on macrophages and dendritic cells (DCs) and activate these cells upon ligand binding. The activation of TLRs basically initiates innate immune response, but can also induce adaptive immune response. TLRs have also been found on epithelial and tumor cells, but their role on tumor cells is still unclear. In some tumor types TLRs promote tumor proliferation and survival, while in others TLR2, -3 and -9 have been shown to be directly involved in apoptosis. Therefore, they seem to be promising candidates for the development of new, effective therapeutic options. It is however necessary to conduct comprehensive studies to assess the significance of these receptors in neoplastic cells. TLR ligands can also be used as immunostimulatory molecules to boost immune system in anticancer treatment. In this respect TLRs have been used in numerous preclinical and clinical studies. However, adjuvants can evoke distinct immune responses, either beneficial or deleterious in the neoplastic setting. Moreover, neoplastic processes may also subvert different signaling pathways and thereby advance cancer progression. From both points of view careful selection of adjuvants is a necessary prerequisite for cancer patients treatment. Thus, TLRs have a dual role, when used as a target for immunostimulation, as well as when used directly to kill the cancer cell.
Keywords: Toll-like receptors, signal transduction, tumor cells, apoptosis, cancer progression, invasiveness, immunotherapy
Current Pharmaceutical Design
Title: Toll-Like Receptors: Cost or Benefit for Cancer?
Volume: 16 Issue: 9
Author(s): T. Matijevic and J. Pavelic
Affiliation:
Keywords: Toll-like receptors, signal transduction, tumor cells, apoptosis, cancer progression, invasiveness, immunotherapy
Abstract: The function of the Toll-like receptor (TLR) family members has been extensively studied in the recent decades. The TLR family is generally involved in the defense against microbial infections. TLRs are expressed mainly on macrophages and dendritic cells (DCs) and activate these cells upon ligand binding. The activation of TLRs basically initiates innate immune response, but can also induce adaptive immune response. TLRs have also been found on epithelial and tumor cells, but their role on tumor cells is still unclear. In some tumor types TLRs promote tumor proliferation and survival, while in others TLR2, -3 and -9 have been shown to be directly involved in apoptosis. Therefore, they seem to be promising candidates for the development of new, effective therapeutic options. It is however necessary to conduct comprehensive studies to assess the significance of these receptors in neoplastic cells. TLR ligands can also be used as immunostimulatory molecules to boost immune system in anticancer treatment. In this respect TLRs have been used in numerous preclinical and clinical studies. However, adjuvants can evoke distinct immune responses, either beneficial or deleterious in the neoplastic setting. Moreover, neoplastic processes may also subvert different signaling pathways and thereby advance cancer progression. From both points of view careful selection of adjuvants is a necessary prerequisite for cancer patients treatment. Thus, TLRs have a dual role, when used as a target for immunostimulation, as well as when used directly to kill the cancer cell.
Export Options
About this article
Cite this article as:
Matijevic T. and Pavelic J., Toll-Like Receptors: Cost or Benefit for Cancer?, Current Pharmaceutical Design 2010; 16 (9) . https://dx.doi.org/10.2174/138161210790963779
DOI https://dx.doi.org/10.2174/138161210790963779 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents and Advances in Hepatocyte-Like Cells Differentiation by Perinatal Stem Cells
Recent Patents on Regenerative Medicine Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface
Recent Patents on CNS Drug Discovery (Discontinued) Immunomodulatory Properties of Thalidomide Analogs: Pomalidomide and Lenalidomide, Experimental and Therapeutic Applications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Forms of Iron Binding in the Cells and the Chemical Features of Chelation Therapy
Mini-Reviews in Medicinal Chemistry Drug Delivery Systems and Strategies to Overcome the Barriers of Brain
Current Pharmaceutical Design Vascularization of Engineered Tissues: Approaches to Promote Angiogenesis in Biomaterials
Current Topics in Medicinal Chemistry Biomarkers of Protein Oxidation in Human Disease
Current Molecular Medicine Signalling Pathways Activated by Ultraviolet Radiation: Role in Ocular and Cutaneous Health
Current Pharmaceutical Design Biomarker Diversity, Validation and Clinical Translation: Tenets for Emergent Personalized Medicine Initiatives
Current Pharmacogenomics and Personalized Medicine AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
Current Gene Therapy Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry Thyroid Hormone Modulation of Immunity: Its Participation in Chronic Stress-Induced Immune Alterations
Current Immunology Reviews (Discontinued) Evolution and Pathogenesis of Oncoviruses Associated with Head and Neck Cancer: History and Current Concepts
Recent Patents on Biomarkers HPV as a Model for the Development of Prophylactic and Therapeutic Cancer Vaccines
Current Molecular Medicine Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Current Pharmaceutical Design Metastatic Melanoma in a Young Woman Treated with TNF-Alpha Inhibitor for Psoriatic Arthritis: A Case Report
Current Drug Safety Planar Cell Polarity Signaling in Collective Cell Movements During Morphogenesis and Disease
Current Genomics An Overview on Keratinocyte Growth Factor: From the Molecular Properties to Clinical Applications
Protein & Peptide Letters RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy
Current Topics in Medicinal Chemistry